 Proto-Oncogene Proteins c-myc
"Proto-Oncogene Proteins c-myc" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Cellular DNA-binding proteins encoded by the c-myc genes. They are normally involved in nucleic acid metabolism and in mediating the cellular response to growth factors. Elevated and deregulated (constitutive) expression of c-myc proteins can cause tumorigenesis.
| Descriptor ID |
D016271
|
| MeSH Number(s) |
D12.776.260.676 D12.776.624.664.700.189 D12.776.660.765
|
| Concept/Terms |
Proto-Oncogene Proteins c-myc- Proto-Oncogene Proteins c-myc
- Proto Oncogene Proteins c myc
- myc Proto-Oncogene Product p62
- myc Proto Oncogene Product p62
- myc Proto-Oncogene Proteins
- Proto-Oncogene Proteins, myc
- myc Proto Oncogene Proteins
- p62(c-myc)
- Proto-Oncogene Products c-myc
- Proto Oncogene Products c myc
- Proto-Oncogene Proteins myc
- Proteins myc, Proto-Oncogene
- Proto Oncogene Proteins myc
- myc, Proto-Oncogene Proteins
- c-myc Proteins
- c myc Proteins
- p62 c-myc
- p62 c myc
|
Below are MeSH descriptors whose meaning is more general than "Proto-Oncogene Proteins c-myc".
Below are MeSH descriptors whose meaning is more specific than "Proto-Oncogene Proteins c-myc".
This graph shows the total number of publications written about "Proto-Oncogene Proteins c-myc" by people in this website by year, and whether "Proto-Oncogene Proteins c-myc" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1989 | 0 | 1 | 1 | | 1990 | 1 | 0 | 1 | | 1991 | 1 | 1 | 2 | | 1992 | 1 | 0 | 1 | | 1993 | 1 | 0 | 1 | | 1994 | 0 | 1 | 1 | | 1995 | 1 | 0 | 1 | | 1996 | 1 | 1 | 2 | | 1997 | 3 | 0 | 3 | | 1998 | 0 | 2 | 2 | | 2000 | 0 | 2 | 2 | | 2001 | 2 | 0 | 2 | | 2002 | 2 | 1 | 3 | | 2003 | 1 | 0 | 1 | | 2004 | 2 | 1 | 3 | | 2005 | 2 | 0 | 2 | | 2006 | 1 | 0 | 1 | | 2007 | 1 | 4 | 5 | | 2008 | 0 | 3 | 3 | | 2009 | 4 | 0 | 4 | | 2010 | 3 | 4 | 7 | | 2011 | 1 | 1 | 2 | | 2012 | 1 | 1 | 2 | | 2013 | 4 | 2 | 6 | | 2014 | 2 | 1 | 3 | | 2015 | 2 | 3 | 5 | | 2016 | 3 | 0 | 3 | | 2017 | 1 | 2 | 3 | | 2018 | 2 | 2 | 4 |
To return to the timeline, click here.
Below are the most recent publications written about "Proto-Oncogene Proteins c-myc" by people in Profiles.
-
Zhang H, Pandey S, Travers M, Sun H, Morton G, Madzo J, Chung W, Khowsathit J, Perez-Leal O, Barrero CA, Merali C, Okamoto Y, Sato T, Pan J, Garriga J, Bhanu NV, Simithy J, Patel B, Huang J, Raynal NJ, Garcia BA, Jacobson MA, Kadoch C, Merali S, Zhang Y, Childers W, Abou-Gharbia M, Karanicolas J, Baylin SB, Zahnow CA, Jelinek J, Graña X, Issa JJ. Targeting CDK9 Reactivates Epigenetically Silenced Genes in Cancer. Cell. 2018 11 15; 175(5):1244-1258.e26.
-
Riedell PA, Smith SM. Double hit and double expressors in lymphoma: Definition and treatment. Cancer. 2018 12 15; 124(24):4622-4632.
-
Mandal M, Maienschein-Cline M, Maffucci P, Veselits M, Kennedy DE, McLean KC, Okoreeh MK, Karki S, Cunningham-Rundles C, Clark MR. BRWD1 orchestrates epigenetic landscape of late B lymphopoiesis. Nat Commun. 2018 09 24; 9(1):3888.
-
Lee J, Zhang LL, Wu W, Guo H, Li Y, Sukhanova M, Venkataraman G, Huang S, Zhang H, Alikhan M, Lu P, Guo A, Galanina N, Andrade J, Wang ML, Wang YL. Activation of MYC, a bona fide client of HSP90, contributes to intrinsic ibrutinib resistance in mantle cell lymphoma. Blood Adv. 2018 08 28; 2(16):2039-2051.
-
Riedell PA, Smith SM. Should We Use Cell of Origin and Dual-protein Expression in Treating DLBCL? Clin Lymphoma Myeloma Leuk. 2018 02; 18(2):91-97.
-
Yang XH, Tang F, Shin J, Cunningham JM. Incorporating genomic, transcriptomic and clinical data: a prognostic and stem cell-like MYC and PRC imbalance in high-risk neuroblastoma. BMC Syst Biol. 2017 Oct 03; 11(Suppl 5):92.
-
Zhang ZC, Liu JX, Shao ZW, Pu FF, Wang BC, Wu Q, Zhang YK, Zeng XL, Guo XD, Yang SH, He TC. In vitro effect of microRNA-107 targeting Dkk-1 by regulation of Wnt/ß-catenin signaling pathway in osteosarcoma. Medicine (Baltimore). 2017 Jul; 96(27):e7245.
-
Carugo A, Genovese G, Seth S, Nezi L, Rose JL, Bossi D, Cicalese A, Shah PK, Viale A, Pettazzoni PF, Akdemir KC, Bristow CA, Robinson FS, Tepper J, Sanchez N, Gupta S, Estecio MR, Giuliani V, Dellino GI, Riva L, Yao W, Di Francesco ME, Green T, D'Alesio C, Corti D, Kang Y, Jones P, Wang H, Fleming JB, Maitra A, Pelicci PG, Chin L, DePinho RA, Lanfrancone L, Heffernan TP, Draetta GF. In Vivo Functional Platform Targeting Patient-Derived Xenografts Identifies WDR5-Myc Association as a Critical Determinant of Pancreatic Cancer. Cell Rep. 2016 06 28; 16(1):133-147.
-
Bouillez A, Rajabi H, Pitroda S, Jin C, Alam M, Kharbanda A, Tagde A, Wong KK, Kufe D. Inhibition of MUC1-C Suppresses MYC Expression and Attenuates Malignant Growth in KRAS Mutant Lung Adenocarcinomas. Cancer Res. 2016 Mar 15; 76(6):1538-48.
-
Huang H, Jiang X, Wang J, Li Y, Song CX, Chen P, Li S, Gurbuxani S, Arnovitz S, Wang Y, Weng H, Neilly MB, He C, Li Z, Chen J. Identification of MLL-fusion/MYC?miR-26?TET1 signaling circuit in MLL-rearranged leukemia. Cancer Lett. 2016 Mar 28; 372(2):157-65.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|